Back to top
more

Ocuphire Pharma (OCUP)

(Delayed Data from NSDQ)

$1.61 USD

1.61
113,234

+0.08 (4.89%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $1.62 +0.01 (0.62%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (76 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Ocuphire (OCUP) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Ocuphire (OCUP) is expected to provide updates on the clinical development of its lead retinal product candidate, APX3330, to treat diabetic retinopathy, in fourth-quarter 2023 earnings release.

Here's Why You Should Invest in Ocuphire Pharma (OCUP) Now

by Zacks Equity Research

Here, we discuss some reasons why buying Ocuphire Pharma (OCUP) stock now may turn out to be a prudent move.

Merck (MRK) Gets EU Nod for Expanded Use in Gastric Cancer

by Zacks Equity Research

Following these approvals, Merck's (MRK) Keytruda is approved for seven gastrointestinal cancers in the European Union. Overall, the drug is approved for 26 indications in the region.

FDA Expands Merck's (MRK) Welireg Label in Renal Cell Carcinoma

by Zacks Equity Research

Per Merck (MRK), the latest FDA approval to Welireg marks the first time a new treatment has been approved in a novel therapeutic class in advanced renal cell carcinoma since 2015.

Moderna (MRNA) Soars on Upbeat Data From Cancer Therapy Study

by Zacks Equity Research

Three-year follow up data from a mid-stage study shows that treatment with Moderna (MRNA)/Merck's cancer combination therapy reduces recurrence/death risk in certain melanoma patients by half.

FDA Updates Labels of Esperion's (ESPR) Cholesterol-Lowering Drugs

by Zacks Equity Research

The label to Esperion's (ESPR) marketed drugs Nexletol and Nexlizet have been updated to include the treatment of primary hyperlipidemia as a qualifier for existing approved populations.

Bears are Losing Control Over Ocuphire Pharma, Inc. (OCUP), Here's Why It's a 'Buy' Now

by Zacks Equity Research

Ocuphire Pharma, Inc. (OCUP) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Is Harmony Biosciences (HRMY) Stock Undervalued Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Viatris (VTRS) Gets FDA Nod for Pupil Dilation Reversal Agent

by Zacks Equity Research

Viatris (VTRS) and partner Ocuphire Pharma receive FDA approval for Ryzumvi to treat pharmacologically-induced mydriasis of the pupils.

MindMed (MNMD) Up on 50% Enrollment in Anxiety Disorder Study

by Zacks Equity Research

MindMed's (MNMD) mid-stage study, evaluating MM-120 for treating general anxiety disorder, reaches over 50% enrollment mark. Its top-line data is expected in late 2023.

FTC Challenges Amgen's (AMGN) $28B Acquisition of Horizon

by Zacks Equity Research

Per the FTC, Amgen's (AMGN) acquisition of Horizon (HZNP) would entrench the monopoly positions for the latter's medications for thyroid eye disease and chronic refractory gout.

PHIO's Skin Cancer Candidate to Enter Clinical Study, Stock Up

by Zacks Equity Research

PHIO surges on the FDA clearance of investigational new drug application for its lead product, PH-762, for the treatment of skin carcinomas.

Here's Why Biogen (BIIB) Stock is Up 12.6% This Year So Far

by Zacks Equity Research

Biogen (BIIB) is set to launch three potential new drugs across four indications in 2023, all in areas of high unmet need.

Arcus (RCUS) & Gilead Re-Collaborate for Inflammatory Diseases

by Zacks Equity Research

Arcus (RCUS) surges as it expands its previous research collaboration with partner Gilead, to focus on developing therapies for inflammatory diseases.

ARS Pharma (SPRY) Gets FDA Panel Vote for Epinephrine Nasal Spray

by Zacks Equity Research

ARS Pharmaceuticals (SPRY) gains as it gets favorable votes from the FDA advisory committee for epinephrine spray to treat severe allergic reactions.

Sarepta's (SRPT) DMD Gene Therapy Gets Endorsed by FDA Panel

by Zacks Equity Research

The FDA's CTGTAC narrowly recommends granting accelerated approval to Sarepta's (SRPT) DMD gene therapy. A final decision from the agency is expected by the end of this month.

ImmunoGen (IMGN) Stock Surges 230% in a Month: Here's Why

by Zacks Equity Research

ImmunoGen (IMGN) shares surge exponentially in the past month owing to the positive data on the expansion study of Elahere for ovarian cancer. An encouraging initial sales uptake of its first marketed product, Elahere, also contribute to the surge.

Reata (RETA) Q1 Earnings Miss, Stock Dips on Pipeline Updates

by Zacks Equity Research

Reata (RETA) incurs wider-than-expected loss in the first quarter. The company discontinues the development of bardoxolone methyl for diabetic kidney disease.

TEVA Q1 Earnings Miss Estimates, Sales Beat, Stock Declines

by Zacks Equity Research

TEVA reports mixed Q1 results, missing earnings estimates but beating the same for revenues. Stock falls.

Amicus (FOLD) Q1 Earnings Miss, Galafold Sales Grow

by Zacks Equity Research

Amicus (FOLD) incurs wider-than-expected loss in the first quarter. Revenues, however, beat estimates. The company reiterates its 2023 guidance.

Halozyme (HALO) Q1 Earnings Disappoint, Revenues Rise Y/Y

by Zacks Equity Research

Halozyme (HALO) first-quarter earnings and revenues miss estimates. The company reiterates its guidance for 2023.

Emergent (EBS) Q1 Earnings Miss Estimates, Revenues Beat

by Zacks Equity Research

Emergent (EBS) reports wider-than-expected first-quarter loss. The company updates its 2023 guidance for selected categories.

Axsome (AXSM) Q1 Earnings Beat Estimates, Auvelity Volume Rises

by Zacks Equity Research

Axsome (AXSM) incurs a narrower-than-expected loss in 1Q23. Its revenues beat estimates and stock gains.

CRISPR Therapeutics (CRSP) Q1 Earnings and Revenues Beat

by Zacks Equity Research

CRISPR Therapeutics (CRSP) provides updates for its gene therapy candidates.

Intra-Cellular (ITCI) Q1 Earnings Top, Caplyta Volume Rises

by Zacks Equity Research

Intra-Cellular (ITCI) first-quarter earnings and revenues beat estimates. The company reiterates its previously issued guidance for 2023.